CCL3 and colorectal carcinoma: The study by Song et al. [50], where lower systemic CCL3 levels correlated with increased CRC risk, suggesting impaired early immune function, is the only epidemiological study to examine pre-diagnostic blood samples in relation to CCL3 and CRC risk, whereas most other investigations have focused on diagnosed patients or tumor tissue, emphasizing progression or prognosis rather than risk.